Wells Fargo Maintains Equal-Weight on GeneDx Hldgs, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Brandon Couillard has maintained an Equal-Weight rating on GeneDx Holdings (NASDAQ:WGS) and raised the price target from $34 to $75.
October 30, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has maintained its Equal-Weight rating on GeneDx Holdings and significantly increased the price target from $34 to $75, indicating a positive outlook.
The significant increase in the price target from $34 to $75 by Wells Fargo suggests a positive outlook for GeneDx Holdings. This could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100